Manila, Philippines — September 1, 2026 — LetsMeds, a trusted provider of specialty oncology medicines, has announced expanded access to Abiraterone Acetate and Enzalutamide medicines for patients and healthcare providers throughout the Philippines.



Prostate cancer remains one of the most commonly diagnosed cancers among men worldwide. As treatment demand continues to grow, consistent access to quality medicines has become increasingly important for hospitals, clinics, pharmacies, and caregivers. LetsMeds is strengthening its oncology supply network by offering reliable generic and branded treatment options at competitive prices.

The company supplies multiple strengths of Abiraterone 250 mg and 500 mg as well as Enzalutamide 40 mg and 160 mg, manufactured in WHO-GMP compliant facilities by established pharmaceutical manufacturers. These medicines are available for individual patient requirements as well as institutional procurement.

“Our goal is to improve access to affordable oncology medicines without compromising quality,” said a spokesperson for LetsMeds. “We are committed to supporting patients and healthcare partners across the Philippines with dependable medicine supply and responsive customer service.”


Key Highlights
Abiraterone Acetate 250 mg & 500 mg available
Enzalutamide 40 mg & 160 mg available
Affordable pricing for the Philippines
Supply support for hospitals, clinics, and pharmacies
Nationwide delivery across the Philippines

Patients and healthcare professionals seeking information about product availability, pricing, or delivery can contact LetsMeds through its official website.